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The search for the elusive Na-K-ATPase-inhibiting natriuretic hormone continues. In this
review, evidence is presented that isolating the carrier protein for natriuretic hormone
from hypertensive plasma is a necessary first step before splitting off the final hormone.
The carrier protein has a molecular weight of 12 kDa while the final hormone has a molec-
ular weight of 408 Da. Both compounds inhibit Na-K-ATPase but the compound containing
the carrier protein predominates. The question has been raised as to whether the carrier
protein is in actuality proANF, a 17 kDa protein that can be split between a 14 kDa protein
(the presumptive proANF) and the 3 kDa ANF.
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INTRODUCTION
Circulating inhibitors of sodium-potassium adenosine triphos-
phatase (Na-K-ATPase) have been shown to be of possible patho-
genetic importance in the mechanism of essential hypertension
(1–3). Although previous studies have demonstrated the pres-
ence of both high-molecular weight (HMW), ranging from 11
to 70 kDa (4–8) and low-molecular weight (LMW) either natri-
uretic or Na-K-ATPase inhibitors, no previous attempts had been
made to ascertain whether HMW or LMW forms predominate
in hypertension. This review summarizes the steps taken by our
laboratory to first identify the HMW form, and then split off the
final LMW form of the hormone. We have in the process deter-
mined the approximate molecular weight of the HMW form and
the precise molecular weight of the LMW form. Unfortunately,
while awaiting the identification of the latter compound, it was
lost due to freezer failures in two different laboratories a continent
apart. This review is presented in intricate detail in the hopes of
encouraging subsequent investigators to pursue the final identifi-
cation of the LMW natriuretic hormone, as well as the identity of
the “carrier protein.”
PREDOMINANCE OF HMW PLASMA Na-K-ATPase
INHIBITOR IN HYPERTENSION
In an initial study (9), plasma samples obtained from 26 patients
with essential hypertension, 12 normotensive controls, and 6 nor-
motensives with a family history of hypertension were separated
into HMW and LMW moieties by passage through a 1 kDa Amicon
membrane. The LMW moiety was separated on C-18 Sep-Pak car-
tridges, applying a 10% stepwise acetonitrile trifluoroacetic acid
gradient. The HMW moiety was further separated on Sephadex
G-75. Sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE)
electrophoresis revealed that the fraction with inhibitory activity
contained a distinct 12 kDa protein band, with staining intensity
depending on the presence or absence of hypertension (Figure 1).
Na-K-ATPase inhibitory activity was found in several LMW frac-
tions, but differences between hypertensives and normotensives
were observed in only the 50% acetonitrile fraction (0.29± 0.12
SD versus 0.11± 0.12µmol/L ouabain equivalents, p< 0.01). Na-
K-ATPase inhibitory activity in the HMW fraction was 38 times
the inhibitory activity in the LMW fraction and was signifi-
cantly increased in hypertensives as compared to normotensive
controls (10.9± 8.9 versus 1.3± 0.8µmol/L ouabain equivalents,
p< 0.01). Inhibitory activity in both HMW and LMW factions
correlated positively with mean blood pressure (r = 0.42, p< 0.05
and r = 0.35, p< 0.05). The inhibitory activity in the HMW frac-
tion, but not the LMW fraction, also correlated positively with
diastolic blood pressure and inversely with the natural log of
plasma renin activity (r = 0.40, p< 0.01). These results indicate
that the HMW moiety is the predominant circulating form of the
Na-K-ATPase inhibitor in hypertension.
DISSOCIATION OF THE LMW Na-K-ATPase INHIBITOR FROM
THE HMW PROTEIN INHIBITOR
Pooled blood samples from 10 patients with well-documented
essential hypertension, not taking any medications for at least
3 weeks, were collected into chilled vacutainers containing sodium
ethylenediamine tetraacetic acid (EDTA) and Trasylol (10). Indi-
vidual samples were also collected from patients with primary
aldosteronism, congestive heart failure (CHF), before and after
treatment, and normal controls. The treatment of congestive fail-
ure employed diuretics and vasorelaxants but avoided digitalis
glycosides.
SDS-PAGE was performed according to the procedure
described by Laemmli (11).
Plasma samples were also passed through a series of Ami-
con membranes, the initial ultrafiltration step employing a 1 kDa
(YM-2) membrane. The retentate was reconstituted in distilled
water and heated for 10 min at 70°C in the presence of 4%
beta-mercaptomethanol and 1 mol/L formic acid. The solution
was cooled down and subsequently placed on a 30 kDa (YM-
30) membrane. The resulting filtrate, containing the dissociated
protein, was lyophilized and subjected to further purification.
The dissociated protein was adsorbed onto a SEP-PAK C-18 car-
tridge. Interfering compounds, e.g., small peptides, hydrophobic
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substances, etc., were retained on the SEP-PAK C-18 cartridge.
The protein of interest was eluted off the SEP-PAK C-18 cartridge
with distilled water. This fraction was lyophilized, reconstituted in
1 mL of distilled water, and subsequently separated on Sephadex
G-75. The plasma preparation was eluted off the column with
10 mmol/L ammonium acetate, pH 6.5. Fractions containing the
Na-K-ATPase inhibitory material (12 kDa protein), which eluted
after the albumin peak, were pooled, lyophilized, and subjected to
a series of assays.
Duplicate bioassay procedures for the natriuretic response of
the 12 kDa protein were performed according to the method
described by Purdy et al. (12). Outcomes were averaged. Results
are displayed in Figure 2.
FIGURE 1 | SDS-PAGE separation of protein bands from plasma from
hypertensives and normotensives. Bands were stained with silver nitrate.
Myoglobin protein markers of 17.2, 14.6, and 8.2 kDa molecular weight and
the locus of the 12 kDa protein are shown in Lane 8. Lane 1: Normotensive
control. Lanes 2 and 3: normotensives with family history of hypertension.
Lanes 4 and 5: hypertensives. Lane 6: normotensive control. Lane 7:
hyperaldosteronism. Plasma samples applied in lanes 2 and 3 were
obtained from the two individuals shown to possess elevated levels of
HMW Na-K-ATPase inhibitor. From Ref. (9) with permission from the editors.
An Econosphere C-18 column was packed with Econosphere
C-18 silica, 5µm particle size. The reversed phase C-18 column
was equilibrated with triple distilled water. The LMW plasma Na-
K-ATPase inhibitor (p-NKAI) was eluted off the column with a
linear acetonitrile gradient (0–100% over a period of 30 min). The
eluate was continuously monitored at 210 nm. One minute frac-
tions were collected, lyophilized, and subsequently tested for the
presence of Na-K-ATPase inhibitory activity.
P-NKAI was further purified by HPLC separation combined
with electrochemical detection using a Model 5100A Coulocomb
Detection System. On reversed phase C18 chromatography, p-
NKAI appeared at 4% acetonitrile, co-eluting with a urinary
inhibitor. P-NKAI was ultrafiltrable through an Amicon YM-05
membrane and thus has a presumed molecular weight of less than
500 Da. Rechromatography of active fractions on a 3µm C-18 col-
umn monitored electrochemically yielded two active compounds,
p-NKAI-1 and p-NKAI-2, both of which were inhibitors of the
Na-K-ATPase enzyme system (Figure 3). P-NKAI-1 caused 50%
inhibition and p-NKAI-2 caused 8% inhibition of Na-K-ATPase in
a volume of inhibitor corresponding to 187µL of original plasma.
The remaining fractions were without inhibitory activity.
The mass spectrum of p-NKAI-1 showed a fairly intense pro-
tonated molecular ion at mass 409 and also the sodium and
potassium adduct ions at masses 431 and 447, respectively. This
would indicate that the molecular weight of p-NKAI-1 is 408 Da
(Figure 4).
A purified hog cerebral cortex Na-K-ATPase preparation was
employed for Na-K-ATPase and K-pNPPase inhibition assays. The
tubes were preincubated with either the 12 kDa protein or the
purified LMW plasma factor for 5 min at 37°C. The enzymatic
reaction was initiated by adding 0.025 mL enzyme preparation
(25 mg/mL). The reaction was stopped by adding 1.0 mL ice cold
10% trichloroacetic acid after an incubation time of 15 min. After
centrifugation, 0.5 mL of supernatant was assayed for inorganic
phosphate according to the procedure described by Fisk and Sub-
barow (13). Both the 12 kDa protein and the LMW plasma factor
FIGURE 2 | Rat natriuretic bioassay of semi-purified 12 kDa protein representing 2.5 mL of original plasma. First arrow designates time of injection of
control solution. The second arrow designates the time of injection of the 12 kDa protein. From Ref. (10) with permission from the editors.
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FIGURE 3 | Elution of semi-purified LMW p-NKAI, monitored
electrochemically. Arrows indicate the loci of p-NKAI-1 and p-NKAI-2. From
Ref. (10) with permission from the editors.
FIGURE 4 | Mass spectroscopy analysis of p-NKAI-1. Note peaks at
masses 409, indicating hydrogen adduct, 431, indicating sodium adduct,
and 447, indicating potassium adduct. The mass of p-NKAI-1 is, therefore,
408. From Ref. (10) with permission from the editors.
(p-NKAI) were shown to inhibit the Na-K-ATPase and K-pNPPase
enzyme systems in a dose-related manner, analogous to ouabain.
The IC50 for inhibition of Na-K-ATPase by p-NKAI corresponds
to 8× 10−7 mol/L ouabain equivalents.
P-NKAI-1 was also tested for its vasoactive properties accord-
ing to the procedure described by Purdy and Weber (14). Isolated
femoral artery segments from New Zealand White rabbits were
sectioned into 3 mm segments, then mounted in a 30 mL tissue
bath containing Krebs-bicarbonate solution aerated continuously
with 95% O2/5% CO2 at 37°C. Subsequently, p-NKAI-1 was
assayed for its vasoactive behavior in the presence and absence
of norepinephrine. A dose–response curve was established for p-
NKAI-1; the concentration of p-NKAI-I yielding 1% contractile
response was selected for the studies of synergy with norepi-
nephrine. One hundred microliters of p-NKAI-1 produced a 1%
contractile response, 300µL produced a 5% contractile response
and 600µL of p-NKAI-1 produced an 18% contractile response.
Similarly, the addition of 100µL of p-NKAI-1 to a bath contain-
ing 10−8 mol/L norepinephrine increased the contractile response
from 60 to 86%.
The dose–response curve for Na-K-ATPase inhibition of the
semi-purified 12 kDa protein paralleled the dose–response curve
for ouabain; 50% inhibition of Na-K-ATPase, corresponding to
5× 10−6 mol/L ouabain, was produced by the 12 kDa inhibitor in
a fraction containing 2.7 mg/mL Lowry protein.
FIGURE 5 | Relative optical densities of 12 and 21 kDa bands. *p<0.05
for CRF, Aldo, EHT compared to normals<50 and for CHF compared to
normals>50. From Ref. (14) with permission.
The 3H ouabain displacement assay revealed that the 12 kDa
protein fraction displaces 3H-ouabain from its receptor in a dose-
related manner, similar to ouabain. There was no cross-reactivity
with digoxin antibody.
COMPARISON OF 12 kDa PROTEIN, MARINOBUFAGENIN,
AND OUABAIN IN VARIOUS DISEASE STATES
In a third study (15), plasma from 101 patients were examined [25
normals (N)< age 50, 13N> age 50, 7 with acute CHF, 24 with
chronic renal failure (CRF), on dialysis, 5 with idiopathic hyperal-
dosteronism (PA), and 27 with essential hypertension, untreated
(EHT)]. Plasma was extracted with 32% acetonitrile, and ana-
lyzed by fluoroimmunoassay (DELFIA) for marinobufagenin and
ouabain. In addition, from 32 patients (6N< 50, 6N> 50, 5 CHF,
5 CRF, 6 EHT, and 4 PA), SDS gradient gels were obtained. The
12 kDa bands were extracted, analyzed for Na-K-ATPase inhibi-
tion, marinobufagenin, and ouabain, and compared to 14 and
21 kDa bands. Marinobufagenin was found to be elevated in
CRF, EHT, PA, and CHF. Ouabain was increased only in PA.
When the relative optical densities of 12 and 21 kDa bands were
contrasted, CRF, PA, and HT were found to be increased and
CHF to be decreased in the 12 kDa band, with no discernible
changes in the 21 kDa bands (Figure 5). Following extraction of
the bands, Na-K-ATPase inhibitory activity measured 38% in 16
pooled 12 kDa bands, with essentially no activity found in the
14 kDa or 21 kDa bands. SDS-PAGE separation of plasma pro-
teins confirmed that the 12 kDa band was elevated in primary
aldosteronism, diminished in CHF, with return toward normal
after treatment (Figure 6). Thus, only the 12 kDa band possessed
all of the attributes of natriuretic hormone.
DISCUSSION
Following an initial flurry of activity, which utilized natriure-
sis as an index of hormone activity, most subsequent studies
of natriuretic hormone have utilized Na-K-ATPase inhibition as
a more rapidly obtained index (1–3). Digitalis-like (EDLF) or
www.frontiersin.org November 2014 | Volume 5 | Article 196 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gonick Carrier protein for natriuretic hormone
FIGURE 6 | SDS-PAGE separation of protein bands from the plasma of
patients with various volume-related disease states. Myoglobin protein
markers of 17.2, 14.6, and 8.2 kDa are shown in lane 1. Lane 2: normal
control. Lane 3: hyperaldosteronism. Lane 4: congestive heart failure,
pre-treatment. Lane 5: congestive heart failure, post-treatment. These gel
separations are from the plasma of individual patients. From Ref. (10) with
permission from the editors.
ouabain-like activities (OLF), measured by radioimmunoassay,
were also initially employed as measures of natriuretic hormone.
But digoxin-like immunoreactivity was found to be non-specific
(16), while the radioimmunoassay for OLF did not prove reliable
when measured by HPLC followed by ELISA (17), or by ultrasen-
sitive UPLC-MS/MS (18). The lower limit of quantification by the
latter method was 1.7 pmol/L, while ouabain was non-detectable.
The suggestion that the presence of endogenous ouabain in human
beings is non-detectable has been vigorously debated by Blaustein
(19). For the moment, therefore, we must consider this an unre-
solved matter. Thus, we are left with the Na-K-ATPase inhibition
assay as presumably the most reliable as well as the most rapid
assay of EDLF activity.
The remaining ouabain-like hormone, which has been sus-
pected to be the putative natriuretic hormone, is marinobufa-
genin (20), for which studies of activity in several diseases have
appeared, including volume-expanded normals (20), CHF (21),
CRF (22), essential hypertension (23), primary aldosteronism
(15), and pre-eclampsia (24). The one noteworthy discrepancy
between natriuretic hormone determined by marinobufagenin
radioimmunoassay and natriuretic hormone, as determined by
the Na-K-ATPase assay, are the findings in CHF [see above and
Ref. (25)]. Urinary sodium values are low in CHF, LMW urinary
Na-K-ATPase inhibitors are also lower than normal (25), and arte-
rial central volume is diminished rather than increased. Kramer
and Kruck (26) found that a natriuretic substance present in an
ultrafiltrate of normal urine from volume-expanded individuals
was absent in the urine of patients with edema related to cirrhosis
with ascites or with nephrotic syndrome, edematous states phys-
iologically similar to CHF. Furthermore, they also demonstrated
that plasma and urine fractions of normal individuals following
Sephadex G-25 separation consistently reduced short-circuit cur-
rent when applied to the serosal surface of frog skin (anti-natriferic
effect) (26), whereas plasma and urine fractions from patients with
edema lacked this effect. In addition, we have shown previously
that although the LMW Na-K-ATPase inhibitor in human urine
has less activity than normal in CHF, the activity reverts toward
normal as CHF improves (25).
The radioimmunoassay for marinobufagenin has been recently
validated by high resolution mass spectrometry but has been mea-
sured only in CRF, where it is elevated (27). Until the CHF results
are similarly verified, it is not possible to be sure that radioim-
munoassay results for marinobufagenin in disease states other than
CRF also reflect the true status.
We suspect that the HMW Na-K-ATPase inhibitor may be a
carrier protein for the LMW inhibitor since the latter can be split
off by use of beta-mercaptoethanol, an agent known to cleave S-S
bonds, plus heat and formic acid, properties employed by Lind-
ner et al. (28) to dissociate oxytocin and vasopressin from their
neurophysin carrier. It is also pertinent that Morich and Garthoff
(5) found that both salt-sensitive (DS) and salt-resistant (DR) rats
displayed two protein bands in their plasma on SDS-PAGE, in the
molecular weight range of 14–15 kDa. When DS rats were given
salt and developed hypertension, the upper band diminished but
the lower band became more intense. The difference in molecular
weight between the two bands was estimated to be between 300
and 400 Da. Mass spectrometry of the first of the LMW inhibitors
in the present study (NKAI-1) revealed a molecular weight of
408 Da, as shown by the hydrogen adduct of 409 Da, the sodium
adduct of 431 Da, and the potassium adduct of 447 Da. The mol-
ecular weight of 408 is identical to that described by Kerek (29),
a biochemist, for an initially identified macrocylic derivative of
inorganic carbon suboxide, which is a natriuretic, Na-K-ATPase
inhibiting compound derived from plant tissue. We look forward
with interest to the comparison between Kerek’s 408 Da compound
and the 408 Da compound discussed in this review.
The HMW compound of the present dissertation was previ-
ously referred to as “hypertension-associated protein” by Van de
Voorde et al. (7). These authors claimed an approximate molecular
weight of 15 kDa for the compound they isolated by chromatog-
raphy after reduction of the disulfide bridges of the precursor
105 kDa protein molecule with beta-mercaptoethanol. In a prior
study of plasma proteins in essential hypertension, utilizing SDS-
PAGE to separate the plasma proteins, Nardi et al. (4) had earlier
reported a 14 kDa protein present in such patients but not in
patients with hypertension secondary to renovascular hyperten-
sion or renal parenchemal disease. Cloix et al. (6) had reported a
13 kDa protein in the plasma of hypertensive human beings and
rats. Thus, we are left with four studies that purport to show either
12, 13, 14, or 15 kDa proteins in the plasma of human beings
with essential hypertension but not in normal controls or possi-
bly in renovascular hypertension or hypertension with CRF. What
could this protein be? In the present study, we have referred to
the 12 kDa protein as a “carrier protein” because the Na-K-ATPase
inhibitor can be split off by heat and formic acid. But are there
alternatives?
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To explore this question in all of its ramifications, it is first
necessary to review what has been learned about the “other”
natriuretic system, namely the natriuretic peptides. Following the
initial description of natriuretic peptides by deBold and asso-
ciates in 1961 (30), it has been found that there are at least three
natriuretic peptides released from the hypothalamus and cardiac
tissue – atrial natriuretic factor (ANF), B-type natriuretic factor
(BNF), and C-type natriuretic factor (CNF). All occur initially
as pre-prohormones, which are degraded to prohormones and
then finally to the active peptides (31).The molecular weight of
the proANF, a circulating compound (32), has been described
as 14 kDa (33). Is it possible that pro-ANF is identical to the
hypertension-associated protein described by Van de Voorde et al.
(7), Nardi et al. (4), Cloix et al. (6), and the present study? A sug-
gestion that this may be the case comes from Melander et al. (34)
who described in offspring of hypertensive human beings a strong
correlation between salt sensitivity, as defined by the difference in
sodium excretion while on a low salt diet and then on a high salt
diet, and plasma proANP levels.
Initially, it was thought that EDLF, endogenous digitalis-like
factor, or OLF, ouabain-like factor, as the Na-K-ATPase inhibitor
became known, could be distinguished physiologically from ANF
by its Na-K-ATPase inhibiting property as well as its tendency to
increase, rather than decrease, vasoconstriction when applied to
isolated blood vessels (10). However, it was recognized by Górny
et al. (35) that ANF does inhibit Na-K-ATPase in the rat renal
medulla, but not in the rat renal cortex, where the proximal tubule
is located. In contrast, Chiou and Vesely (36) reported that kali-
uretic peptide, a fraction split off from ANF prohormone, inhibits
both renal cortical and medullary Na-K-ATPase. However, these
experiments employed rat renal tissue rather than hog cerebral
cortex for assay of Na-K-ATPase and the inhibition in the two
studies quoted resulted from indirect inhibition of Na-K-ATPase
through effects of second messengers, namely, dopamine in the
first study (35) and prostaglandin E2 in the second study (36).
Thus, we may no longer be able to depend exclusively on the Na-
K-ATPase assay to distinguish between ANF and EDLF. On the
other hand, we can still depend on both the molecular weight
and the direct vasoconstrictive (10) or vasodilatory (37) actions
on isolated vascular smooth muscle preparations to distinguish
between EDLF and ANF. The molecular weights for EDLF have
been reported as varying between 360 and 620 Da (Table 1), while
the molecular weights for ANF have been described as 3800 Da for
rat ANF (38) and varying from 3000 Da (33) to 5499 Da (39) for
human ANF.
Haupert (44) in 1988 first posed the question as to whether
there is an interrelationship between natriuretic peptides and
EDLF or OLF. That the interrelationship exists can no longer
be in doubt. It has long been recognized that both ANF and
EDLF are released from the hypothalamus (45, 46), and in fact
from the AV3V region (47). Lesions produced in the AV3V region
prevent the natriuresis following isotonic saline volume expan-
sion in experimental animals. Furthermore blood drawn following
expansion failed to show an anti-natriferic effect in the toad blad-
der in contrast to control animals, implying interference with
release of the Na-K-ATPase inhibitor. The perfusate from incu-
bation of fragments of rat brain inhibited the Na, K pump by a
Table 1 | Comparison of sources and molecular weights of various
EDLFs.
Author Source Molecular
weight
(daltons)
Reference
Bricker et al. Human uremic urine 360 (40)
McKinnon et al. Human placenta 370 (41)
Kramer et al. Na-loaded normal human urine 391 (38)
Cloix et al. Normal human urine 431 (42)
Weiler et al. Hypertensive human plasma 408 (10)
Kerek Plant tissue 408 (29)
Tamura et al. Pig urine 620 (43)
77% reduction of ouabain-sensitive 86Rb uptake into human ery-
throcytes. This did not occur when ANF was given intravenously
before sacrifice of the test animals (48). ANF injected into lateral
cerebral ventricles releases an Na-K-ATPase inhibitor measured as
above in cultured aortic smooth muscle cells (49). Ouabain and
digoxin, cardiotonic steroids resembling EDLF and OLF, increase
ANF secretion by rat atrial cardiocyte superfusions (50). Liu et al.
(51) also employed the perfused beating rabbit atria model to
show that ouabain significantly increased ANF secretion in a dose-
dependent manner, indicating that the interrelationship between
Na-K-ATPase inhibitors and ANF can proceed in both directions.
Finally, in an elegant experiment performed by Morgan et al.
(52), using extracts from cultured rat hypothalamic cells separated
on Sephadex G-25, a sodium transport inhibitor could be recov-
ered from the post-salt fraction as indicated by three assays: (1)
inhibition of transport in human erythrocytes, (2) displacement
of 3H ouabain from its binding site, and (3) direct inhibition of
canine Na-K-ATPase. Could pro-ANF and EDLF be co-secreted by
the hypothalamus in response to volume expansion or as an indi-
cator of pre-disposition to essential hypertension? A suitable way
to settle this question would be to perform immunoassays for pro-
ANF and ANF on the 12 kDa protein of the present experiment.
For this reason, I would again implore currently active investi-
gators to separate the 12 kDa protein from human hypertensive
plasma and test it for pro-ANF and ANF immunoreactivity.
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